Marlise R. Luskin, MD, MSCE, discussed treatment options for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and ...

DelveInsight's 'BREYANZI Market Size, Forecast, and Market Insight Report' highlights the details around BREYANZI, a CD19-directed CAR ...

Common chemotherapy drugs such as vincristine (Sh300 per vial), cyclophosphamide (Sh350 per vial), cisplatin (Sh700), doxorubicin (Sh900), and cytarabine (Sh400) have remained relatively stable in ...

BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies ...